Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah, there's no way we'll see anything before November 2022.
Once they finish patient enrollment it will take another 10 months to collect the data + 2 months to go through it and get the PR ready.
At this rate we're not getting any results until Christmas next year.
Hurts to see these biotech fails even when I don't own shares in the company.
-70% pre-market. Ouch.
The party goes on until one day it doesn't. If Biogen can get their drug approved and make money off it then so can the others.
I'd say $8 is a better price to pick up more. When it goes to $12 you can then cash in a neat 50% profit.
Probably heading towards $7 or $8.
Worth mentioning is that bryo fixes this problem upstream and that this is just one of its benefits.
https://pubmed.ncbi.nlm.nih.gov/22700373/
"Activation of the a-secretase processing pathway of amyloid precursor protein (APP) is recognized as an important mechanism which diverts APP processing from production of beta-amyloid (Aß) to non toxic sAPPa, decreasing Alzheimer's disease (AD) plaque formation and AD-associated cognitive deficits."
"Because bryostatin-1 is a highly potent PKC-d and -e activator which activates a-secretase APP processing, further characterization of bryostatin-1/bryologues may help refine their use as important tools for the clinical management of AD."
Would rather have it stay in the single digits so I can pick up more shares tbh
Guess I'll start calling it the $6-13 range then lol
We did hit $14 but it didn't last very long.
Give it a few more days and you'll see
Back in the $6-12 range now. If I owned more shares I would start selling some at the highs and buy them back at the lows because of how predictable this thing is getting.
Let's see if it holds. Lots of warrants can be exercised for a profit at the current price.
Market doesn't care about what's fair or unfair. It's what buyers are willing to buy for vs what sellers are willing to sell for.
If you think the price is too cheap then you're welcome to buy the shares that sellers don't want.
Updated count won't be out until November. The websites get their information from SEC filings.
Is it just me or does this stock not have an options market? Nasdaq website says option chain is unavailable.
Feels like a ticking time bomb honestly. Will it turn back and move towards $7 again or is this the one that keeps it above $12?
You never know.
PKC and its effects on memory has been studied for a long time now. Makes sense why AD patients can't form new memories if they lack an enzyme required for memory formation.
It would be like trying to write something on a piece of paper while your pen has run out of ink.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1283453/
https://pubmed.ncbi.nlm.nih.gov/24484697/
From pages 234-235 in Memory's Voice (keep in mind that this was written in 1992):
"As the disease progresses, the lacunae of memory become less sub-
tle. Short-term lapses begin to appear. A patient may forget an
appointment he made a few hours earlier. As is common with simple
aging, some individuals compensate by writing down everything they
want to remember. Insidiously, the disease begins to consume pieces of
more permanent memory-the name of a grandchild is confused with
that of a brother; a doctor's address is substituted for that of a priest. A
watchmaker can still repair watches, but he doesn't know where he
works or that this is the means of his livelihood. At home, he no longer
pays the bills and ultimately forgets daily necessities such as when to
take out the trash. Throughout the early deterioration of life, patients
seem to sense the havoc the disease is wreaking. They seem to reach
for what is missing and are often anxious in their helplessness. But it is
the family members who feel the greatest anxiety and helplessness and
on whom the burden of the patient's daily care usually falls. Finally, the
results of diffuse brain destruction, no longer limited to memory loss,
extend to the loss of sensations and emotion, impaired movement, and
uncontrolled bodily functions.
To the student of memory, Alzheimer's disease presents a tempting
target. But is it, in fact, truly a disease of memory, or is memory impair-
ment a characteristic symptom simply because the disease affects so
many brain regions? Yet, doesn't the course of Alzheimer's track the
permanence of memory? At first patients forget what they learned a
few weeks ago, then a few days ago, and finally only moments ago.
They progressively lose the ability to consolidate and store a memory
for any length of time. This is undoubtedly due to destruction of
the hippocampus by plaques, as well as damage to other brain areas
where plaques are found, but there is no one-to-one correspondence
between plaque deposit and symptom occurence. Furthermore, in
older people plaques can appear without any Alzheimer's symptoms.
Pursuing the relation of Alzheimer's disease to memory loss fur-
ther, we can ask if the disease, at its onset, affects molecular events
unique to memory. Perhaps there is a subtle loss in sensory discrimina-
tion of particular odors, sound, or colors. Maybe there is a slight loss of
coordination or loss of balance. Recent evidence suggests that a pri-
mary site for the disease could be protein kinase C, the enzyme that our
laboratory has implicated in associative memory. Saitoh and his
colleagues reported a deficiency in this enzyme within cells taken from
Alzheimer patients as compared to nonpatients of the same age. Other
workers have begun to observe hints of impairment in the biochemical
steps required to generate the second messengers that activate protein
kinase C. Still other investigators have shown that biochemical steps in
the formation of beta-amyloid, a key molecule in plaque formation,
involve protein kinase C activation. A genetic basis for Alzheimer's dis-
ease has also been linked to the beta-amyloid protein in a small per-
centage of cases. There may be in every human a potential for any one
of many molecular steps in our neurons to break down. With age, the
probability for one or more of these steps to go awry may increase,
accounting for the increasingly high incidence of Alzheimer's disease
with age. An analogous biochemical vulnerability may explain the
increasingly high incidence of cancer with age."
Recruitment is about 75% complete. My guess is they push out a PR in November or December.
The Ameritrade video felt very coordinated. What are the odds that a stock triggers circuit breakers right in the middle of an interview where everyone can see it?
I'm optimistic about the science but there's no denying the fact that there are some questionable things going on with the business side of this company.
Could be, but it sure isn't Benzinga that caused all this volume lol
Why would the article have anything to do with this? Serious investors don't read Benzinga.
There's been plenty of days where the volume hit a million or more on no news.
Also worth mentioning is that the man worked on artificial neural networks 20-30 years before they became mainstream:
https://www.semanticscholar.org/paper/Dynamically-stable-associative-learning-(DYSTAL)%3A-a-Vogl-Alkon/24320b386ccf0d0b63e73cb431019fe1bffbeb45
The more I read about his research, the more it makes sense to go after PKCe as a target for AD.
Here's a paper about "memory kinases":
https://pubmed.ncbi.nlm.nih.gov/24484697/
The warrants have already been registered and can be exercised at any time. You get one share for each exercised warrant and in return you have to pay the company the amount specified for each warrant. No need to report the new shares since they have already been registered.
I think you can either pay directly or have your broker pay and give you a short term loan so you can pay it back with money you make from selling your new shares.
Not sure about specific details though. You'd have to ask someone that has actually acquired and exercised those warrants.
7 months is plenty of time to exercise those warrants and I would say keeping a lid on prices is good news for buyers looking to acquire more before results.
He's better suited as an advisor imo. Directors decide the long-term objectives of a company, and for Synaptogenix I would hope that Dr. Alkon is the one making the scientific decisions rather than an outsider like Dr. Perry.
Lots of time left to make a decision. This stock has a habit of swinging up and down within a certain range before results.
Added the latest presentation to the ibox:
Yet another mouse study trying to prove the amyloid hypothesis.
Read this article for more info:
https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/
Might also be available in other stores but here's where I got my used copy:
https://www.amazon.com/Memorys-Voice-Deciphering-Brain-Mind-Code/dp/0060183004/
Thanks, looking forward to reading the paper. I'm currently reading Dr. Alkon's book on memory and it's interesting to see how many decades he has spent on mapping mental functions to physical processes happening inside the brain.
Lots of stuff in there that is still relevant today.
The story behind 'probably the worst drug approval decision in recent US history':
https://edition.cnn.com/2021/09/26/politics/alzheimers-drug-aduhelm-fda-approval/index.html
No doubt that good data would send this to the moon, but there is a long time left before that data gets released.
I still don't see why this would take off because of some minor PRs before the big one.
It's up from the 6s after falling from the 12s and institutional ownership is below 15%.
Clearly the market is not interested, and there's no new data being reported until late next year.
Feel free to buy more shares if you think this is worth $50.
Lots of speculation about higher prices here but nobody seems willing to buy up the supply that is available for single digit prices.
Slowing the decline is better than nothing, and now it might just be enough to keep patients alive until a real treatment is available that can reverse the decline.
Same logic is applied to anti-aging drugs where they're trying to delay age-related damage before attempting to repair it.
You would expect that doctors and researchers are smart enough to not make such a basic mistake.
Hopefully they will publish a paper that explains it all.
There are two big questions about the last trial though:
1. Why did the most severe patients not respond to the treatment like the other groups did?
2. Why did the placebo group perform so well?
The first one could be explained by a severe lack of surviving neurons making it impossible to reconstruct the network through synaptogenesis, but the second one? I don't think any AD trial has ever had a placebo group perform so well.
Feels like more of the same honestly. Bobbing up and down like a rubber duck, and now it's time for some up after the down.
He said enrollment is 2/3 complete. The trial as a whole won't be completed until later next year.
$6-12 until results with occasional spikes outside that range.
At first I was just guessing but the price movement keeps proving me right lol